Biomarkers for severe eosinophilic asthma.
The last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that blood eosinophil counts, rather than sputum or tissue eosinophil counts, evolved as a pharmacodynamic and predictive biomarker for the efficacy of treatment with mepolizumab in patients with severe eosinophilic asthma. Based on the available ev...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
(Version of record, pdf, 416.5KB)
- Publisher copy:
- Pubs id:
- Local pid:
- Deposit date:
- Copyright holder:
- Pavord et al
- Copyright date:
- © 2017 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma and Immunology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
If you are the owner of this record, you can report an update to it here: Report update to this record